No Data
No Data
Is Syndax Pharmaceuticals (NASDAQ:SNDX) A Risky Investment?
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $41
TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...